High-Grade Progression Confers Poor Survival in Pancreatic Neuroendocrine Tumors

Abstract

Introduction: Little is known about how pancreatic neuroendocrine tumors (PanNETs) evolve over time and if changes toward a more aggressive biology correlate with prognosis. The purpose of this study was to characterize changes in PanNET differentiation and proliferation over time and to correlate findings to overall survival (OS). Patients and Methods: In this retrospective cohort study, we screened 475 PanNET patients treated at

Fibrinogen/Albumin Ratio as a Promising Marker for Predicting Survival in Pancreatic Neuroendocrine Neoplasms

“…Pan-NENs are a heterogeneous disease with different prognoses in different subgroups. 4,5 In addition to the existing tumor-node-metastasis (TNM) staging system, 6 tumor grade, 7 and differentiation status, 8 there are a number of emerging markers for predicting the prognosis of patients with Pan-NENs, including the blood glucose level, 9 peripheral blood neutrophil/lymphocyte ratio 10 and some other peripheral blood test markers. However, no studies have explored the prognostic value of the fibrinogen/albumin ratio (FAR) in Pan-NENs.…”

Difficulties in the diagnosis and treatment of malignant paraganglioma of the urinary bladder

“…of the disease was noted in approximately 20% of the patients [4]. Lately, it has been shown that longitudinal increase in Ki-67 index and tumour grade was a common feature of pancreatic neuroendocrine tumours, and it was linked to a poor outcome [5]. We speculate that, in our case, transformation of metastases to higher grade (with doubled Ki-67 index compared to primary lesion), confirmed in histopathological examination of the lymph node, could be the reason for PRRT treatment failure regardless of very good somatostatin receptor expression on baseline tumour cells.…”

Altered expression of striatin‑4 is associated with poor prognosis in bladder transitional cell carcinoma

“…Muscle infiltration, pathological grade and microvascular invasion were listed as some of the most crucial factors for evaluating patient survival time and prognosis. The association between these variables and patient outcome is not strictly confined to bladder cancer, but also in other malignancies (32)(33)(34). Hence, STRN4 may serve a role as an independent prognostic factor.…”